Chemotherapy advances in head and neck oncology

Research output: Contribution to journalArticle

Abstract

Chemotherapy has an expanding role in the treatment of squamous cell carcinoma of the head and neck. Patients with recurrent or metastatic disease that have a good performance status should receive combination therapy with cisplatin and 5-fluorouracil or enter investigational protocols. Neoadjuvant chemotherapy should be offered to patients with laryngeal carcinoma as an alternative to surgery. Adjuvant chemotherapy should be considered in patients with an increased risk for relapse. Combined chemoradiotherapy may improve locoregional control and impact on survival. Chemoradiotherapy warrants further investigation through clinical trials and should be considered for patients at high risk for relapse. As the biology of these tumors becomes better defined, so too will our ability to define subsets of patients who may benefit from combined modality treatment.

Original languageEnglish (US)
Pages (from-to)265-271
Number of pages7
JournalSeminars in Surgical Oncology
Volume11
Issue number3
DOIs
StatePublished - 1995

Fingerprint

Neck
Head
Drug Therapy
Chemoradiotherapy
Recurrence
Adjuvant Chemotherapy
Fluorouracil
Cisplatin
Therapeutics
Clinical Trials
Carcinoma
Survival
Neoplasms

Keywords

  • adjuvant chemotherapy
  • chemotherapy
  • head and neck cancer
  • neoadjuvant chemotherapy

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Chemotherapy advances in head and neck oncology. / Liggett, W.; Forastiere, Arlene A.

In: Seminars in Surgical Oncology, Vol. 11, No. 3, 1995, p. 265-271.

Research output: Contribution to journalArticle

@article{8ed4089814824c9e91e546cab27ec91a,
title = "Chemotherapy advances in head and neck oncology",
abstract = "Chemotherapy has an expanding role in the treatment of squamous cell carcinoma of the head and neck. Patients with recurrent or metastatic disease that have a good performance status should receive combination therapy with cisplatin and 5-fluorouracil or enter investigational protocols. Neoadjuvant chemotherapy should be offered to patients with laryngeal carcinoma as an alternative to surgery. Adjuvant chemotherapy should be considered in patients with an increased risk for relapse. Combined chemoradiotherapy may improve locoregional control and impact on survival. Chemoradiotherapy warrants further investigation through clinical trials and should be considered for patients at high risk for relapse. As the biology of these tumors becomes better defined, so too will our ability to define subsets of patients who may benefit from combined modality treatment.",
keywords = "adjuvant chemotherapy, chemotherapy, head and neck cancer, neoadjuvant chemotherapy",
author = "W. Liggett and Forastiere, {Arlene A.}",
year = "1995",
doi = "10.1002/ssu.2980110312",
language = "English (US)",
volume = "11",
pages = "265--271",
journal = "Journal of Surgical Oncology",
issn = "0022-4790",
publisher = "Wiley-Liss Inc.",
number = "3",

}

TY - JOUR

T1 - Chemotherapy advances in head and neck oncology

AU - Liggett, W.

AU - Forastiere, Arlene A.

PY - 1995

Y1 - 1995

N2 - Chemotherapy has an expanding role in the treatment of squamous cell carcinoma of the head and neck. Patients with recurrent or metastatic disease that have a good performance status should receive combination therapy with cisplatin and 5-fluorouracil or enter investigational protocols. Neoadjuvant chemotherapy should be offered to patients with laryngeal carcinoma as an alternative to surgery. Adjuvant chemotherapy should be considered in patients with an increased risk for relapse. Combined chemoradiotherapy may improve locoregional control and impact on survival. Chemoradiotherapy warrants further investigation through clinical trials and should be considered for patients at high risk for relapse. As the biology of these tumors becomes better defined, so too will our ability to define subsets of patients who may benefit from combined modality treatment.

AB - Chemotherapy has an expanding role in the treatment of squamous cell carcinoma of the head and neck. Patients with recurrent or metastatic disease that have a good performance status should receive combination therapy with cisplatin and 5-fluorouracil or enter investigational protocols. Neoadjuvant chemotherapy should be offered to patients with laryngeal carcinoma as an alternative to surgery. Adjuvant chemotherapy should be considered in patients with an increased risk for relapse. Combined chemoradiotherapy may improve locoregional control and impact on survival. Chemoradiotherapy warrants further investigation through clinical trials and should be considered for patients at high risk for relapse. As the biology of these tumors becomes better defined, so too will our ability to define subsets of patients who may benefit from combined modality treatment.

KW - adjuvant chemotherapy

KW - chemotherapy

KW - head and neck cancer

KW - neoadjuvant chemotherapy

UR - http://www.scopus.com/inward/record.url?scp=0029037071&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029037071&partnerID=8YFLogxK

U2 - 10.1002/ssu.2980110312

DO - 10.1002/ssu.2980110312

M3 - Article

C2 - 7638514

AN - SCOPUS:0029037071

VL - 11

SP - 265

EP - 271

JO - Journal of Surgical Oncology

JF - Journal of Surgical Oncology

SN - 0022-4790

IS - 3

ER -